+++
title = "Monogram Technologies Secures Regulatory Approval for Robotic Knee Replacement Trial in India"
date = "2025-04-30T19:55:18Z"
draft = false
summary = "<p>Monogram Technologies (NASDAQ: MGRM) has received approval from India’s Central Drugs Standard Control Organization to import its mBôs TKA system and begin a 102-patient clinical trial in partnership with Shalby Limited (NSE: SHALBY) to evaluate the safety and effectiveness of its robotic total knee replacement system.</p><p>CEO Benjamin Sexson called the approval a major milestone toward commercial launch, while partners from Reliance Life Sciences and Shalby praised the trial’s potential to elevate global orthopedic standards, with surgeries expected to begin within 90 business days.</p>"
description = "Monogram Technologies, a robotics company, gets approval for clinical trial in India to evaluate its robotic knee replacement system with partners Shalby Limited and Reliance Life Sciences, marking a milestone in orthopedic surgery advancements."
source_link = "https://rss.investorbrandnetwork.com/ainw/ainewsbreaks-monogram-technologies-inc-nasdaq-mgrm-secures-indian-regulatory-approval-for-robotic-knee-surgery-clinical-trial/"
enclosure = "https://cdn.newsramp.app/banners/frontier-tech-3.jpg"
article_id = 85398
feed_item_id = 13666
url = "2025-04-30-monogram-technologies-secures-regulatory-approval-for-robotic-knee-replacement-trial-in-india"
qrcode = "https://cdn.newsramp.app/ibn/qrcode/254/30/chipCuU9.webp"
source = "InvestorBrandNetwork (IBN)"
+++

<p>Monogram Technologies, a pioneer in AI-driven robotics, has achieved a pivotal milestone with the regulatory approval from India's Central Drugs Standard Control Organization for its comprehensive clinical trial on the mBôs TKA system. This innovative robotic total knee replacement system is set to undergo a multi-center study involving 102 patients, aiming to assess its safety and effectiveness. The trial, a collaboration with Shalby Limited, will feature a three-month clinical follow-up across various healthcare sites in India, with Monogram providing full-time staff to ensure the study's success.</p><p>The mBôs system represents a leap forward in orthopedic surgical technologies, designed to autonomously perform high-precision implant insertions. By leveraging advanced technologies such as 3D printing, machine vision, artificial intelligence, and next-generation robotics, Monogram aims to deliver personalized knee implants that could significantly enhance patient outcomes and surgical accuracy. This trial is not just a test of the system's capabilities but a critical step towards its potential global implementation, with implications for setting new standards in orthopedic surgery.</p><p>CEO Benjamin Sexson views this regulatory approval as a cornerstone for the commercial launch of the mBôs system, underscoring the company's commitment to advancing surgical methodologies. With FDA clearance already secured for its mPress implants and a pending 510(k) clearance for its robotic products, Monogram is at the forefront of integrating cutting-edge technology into healthcare. The enthusiasm from partners like Reliance Life Sciences and Shalby highlights the trial's significance, not just for Monogram but for the future of orthopedic surgery worldwide.</p><p>The implications of this trial extend beyond the immediate benefits to patients and surgeons. It represents a broader shift towards personalized, technology-driven healthcare solutions that could redefine treatment standards across the globe. For business and technology leaders, Monogram's progress underscores the growing intersection of AI, robotics, and healthcare, offering a glimpse into the future of medical innovation and its potential to transform industries.</p>